INDP
vs
S&P 500
INDP
S&P 500
Over the past 12 months, INDP has underperformed S&P 500, delivering a return of -91% compared to the S&P 500's +13% growth.
Stocks Performance
INDP vs S&P 500
Performance Gap
INDP vs S&P 500
Performance By Year
INDP vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Indaptus Therapeutics Inc
Glance View
Indaptus Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on enhancing and expanding curative cancer immunotherapy for patients with unresectable or metastatic solid tumors and lymphomas. The company designs its approach by targeting specific tumor or viral antigens. Its lead candidate, Decoy20, is in pre-clinical development. Its platform is based on the hypothesis that require anti-tumor immunotherapy to activate both innate and adaptive cellular immunity in both tumors and immune organs. Its approach uses multi-targeted package of bacterial pathogen-associated molecular patterns (PAMPs) in the form of attenuated and killed, intact but non-pathogenic bacteria delivered intravenously. Its intravenous therapeutic candidates target the liver, spleen, and leaky vasculature of tumors, producing immune activation in an immune organ, as well as a common site for primary and metastatic cancer and hepatitis B virus (HBV) infection.
